Potent and selective inhibitors of Akt kinases slow the progress of tumors <i>in vivo</i>
Yan Luo, Vincent L. Giranda(Abbott Fund), Keith W. Woods(Abbott Fund), Ron de Jong(Takeda (United States)), Phong Nguyen(Howard Hughes Medical Institute), Vered Klinghofer(Abbott Fund), Yan Shi(Abbott Fund), Vincent S. Stoll, Jennifer J. Bouska(Abbott Fund), Tilman Oltersdorf(Idera Pharmaceuticals (United States)), Emily E. Gramling-Evans, Anatol Oleksijew(Abbott Fund), Richard A. Smith, Jessica A. Powlas, Ran Guan(Abbott Fund), Amanda K. Mika(Abbott Fund), Tongmei Li, Eric F. Johnson(Scripps Research Institute), Qun Li, Xuesong Liu(Beth Israel Deaconess Medical Center), Sheela A. Thomas(Abbott Fund), Alexander R. Shoemaker(Abbott Fund), Thomas McGonigal(Abbott Fund), Saul H. Rosenberg(AbbVie (United States)), Edward K. Han(Abbott Fund), Mulugeta Mamo, Michael J. Mitten(Abbott Fund), Bradley A. Zinker(Abbott (United States))
Cited by 244
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k